Anticorps Polyclonal de lapin anti-EPS8L3

EPS8L3 Polyclonal Antibody for WB, ELISA

Hôte / Isotype

Lapin / IgG

Réactivité testée

Humain

Applications

WB, ELISA

Conjugaison

Non conjugué

N° de cat : 32571-1-AP

Synonymes

Epidermal growth factor receptor kinase substrate 8-like protein 3, Epidermal growth factor receptor pathway substrate 8-related protein 3, EPS8 Signaling Adaptor L3, EPS8-like protein 3, EPS8R3



Applications testées

Résultats positifs en WBcellules HepG2,

Dilution recommandée

ApplicationDilution
Western Blot (WB)WB : 1:5000-1:50000
It is recommended that this reagent should be titrated in each testing system to obtain optimal results.
Sample-dependent, check data in validation data gallery

Informations sur le produit

32571-1-AP cible EPS8L3 dans les applications de WB, ELISA et montre une réactivité avec des échantillons Humain

Réactivité Humain
Hôte / Isotype Lapin / IgG
Clonalité Polyclonal
Type Anticorps
Immunogène EPS8L3 Protéine recombinante Ag38525
Nom complet EPS8-like 3
Masse moléculaire calculée67kDa,593aa
Poids moléculaire observé65 kDa
Numéro d’acquisition GenBankNM_001319952.1
Symbole du gène EPS8L3
Identification du gène (NCBI) 79574
Conjugaison Non conjugué
Forme Liquide
Méthode de purification Purification par affinité contre l'antigène
Tampon de stockage PBS with 0.02% sodium azide and 50% glycerol
Conditions de stockageStocker à -20°C. Stable pendant un an après l'expédition. L'aliquotage n'est pas nécessaire pour le stockage à -20oC Les 20ul contiennent 0,1% de BSA.

Informations générales

EPS8L3 (epidermal growth factor receptor kinase substrate 8-like protein 3) is a member of the EPS8 family, encoding a protein associated with the epidermal growth factor receptor (EGFR) signaling pathway. Studies have shown that EPS8L3 is highly expressed in a variety of tumors, such as hepatocellular carcinoma (HCC), pancreatic cancer, and gastric cancer, and is closely associated with tumor proliferation, migration, and invasive ability. It promotes tumor cell proliferation and inhibits apoptosis by activating GSK3β and PI3K/AKT/mTOR signaling pathways. In addition, high expression of EPS8L3 is associated with poor prognosis in tumor patients and may serve as a biomarker for tumor diagnosis and prognostic assessment. Due to its important role in tumors, EPS8L3 is considered a potential therapeutic target, and its inhibition may enhance the efficacy of multi-target kinase inhibitors.

Protocole

Product Specific Protocols
WB protocol for EPS8L3 antibody 32571-1-APDownload protocol
Standard Protocols
Click here to view our Standard Protocols
{{ptg:RelatedPrimaryAntibodies}}